Dijon, France

Nicolas Baumard

This inventor holds 1 USPTO granted patent, plus 1 CIPO patent and 1 EPO patent. Top assignee: Crossject. Active years: 2022.


% Patents Active = 100.0


 

Average Co-Inventor Count = 3.0

ph-index = 1


Company Filing History:


Years Active: 2022

Loading Chart...
Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Nicolas Baumard: Innovator in Pharmaceutical Solutions

Introduction

Nicolas Baumard is a notable inventor based in Dijon, France. He has made significant contributions to the field of pharmaceuticals, particularly in the development of solutions for critical medical conditions. His innovative work focuses on enhancing the efficacy of adrenaline treatments.

Latest Patents

Nicolas Baumard holds a patent for an adrenaline pharmaceutical solution designed for an injection device. This solution includes adrenaline or a pharmaceutically-acceptable salt thereof, vitamin E TPGS, a chelating agent, and a solvent. The method is particularly relevant for treating anaphylactic shocks, cardiac arrests, asthma, and cardiocirculatory distresses. Additionally, it encompasses an injection kit that includes both the injection device and the pharmaceutical solution.

Career Highlights

Baumard is associated with Crossject, a company that specializes in innovative drug delivery systems. His work at Crossject has positioned him as a key player in the pharmaceutical industry, focusing on solutions that can save lives in emergency situations.

Collaborations

Nicolas collaborates with talented professionals such as Audrey Ressejeac and Eric Teillaud. Their combined expertise contributes to the advancement of medical technologies and the development of effective treatment solutions.

Conclusion

Nicolas Baumard's contributions to pharmaceutical innovations, particularly in adrenaline solutions, highlight his commitment to improving medical treatments. His work continues to have a significant impact on emergency healthcare practices.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…